Table 1 Demographics of the PDxBr training and validation cohorts
Train (N = 1559) | Validation (N = 516) | |
|---|---|---|
Median age, y (range) | 60 (24, 90) | 60 (28, 90) |
Race/ethnicity, N (%) | ||
Asian | 9 (0.6) | 6 (1) |
Black | 81 (5) | 21 (4) |
Latino | 22 (1) | 8 (1) |
Other | 186 (12) | 69 (13) |
Unknown | 408 (26) | 128 (25) |
White | 853 (55) | 284 (55) |
Estrogen receptor, N (%) | ||
0 | 204 (13) | 68 (13) |
1 | 1355 (87) | 448 (87) |
Progesterone receptor, N (%) | ||
0 | 292 (19) | 100 (19) |
1 | 1267 (81) | 416 (81) |
HER2, N (%) | ||
0 | 1362 (87) | 461 (89) |
1 | 197 (13) | 55 (11) |
Tumor size (cm) | 1.5 ± 1.1 (0.1, 17.0) | 1.5 ± 0.9 [0.1, 8.0] |
T1 | 1168 (75) | 398 (77) |
T2 | 367 (24) | 112 (22) |
T3 | 24 (2) | 6 (1) |
Stage | ||
Stage1 | 1055 (68) | 362 (70) |
Stage 2 | 386 (25) | 123 (24) |
Stage IIIA/B | 81 (5) | 21 (4) |
Stage IIC | 36 (2) | 10 (2) |
Stage IV | 1 (0.1) | 0 (0) |
Lymph node status | ||
posLN = 0 | 1075 (69) | 350 (68) |
microLN or isolatedLN and posLN = 0 | 127 (8) | 56 (11) |
1 ≤ posLN ≤ 3 | 239 (15) | 79 (15) |
posLN > 3 | 118 (8) | 31 (6) |
Grade | ||
1 | 290 (19) | 68 (13) |
2 | 649 (42) | 219 (42) |
3 | 620 (40) | 229 (44) |
Total events | ||
0 | 1339 (86) | 447 (87) |
1 | 220 (14) | 69 (13) |
Time to event (months) | 75.3 [-16.0, 68.0, 200.0] | 79.4 [0.0, 69.0, 1173.0] |